SCHEMBL23698267

SCHEMBL23698267

O=[C]Nc1cccc2ccc3ccccc3c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 4/20 0.43
CYP1A2 P05177 3/20 0.43
THRB P10828 1/20 0.43
KDM4E B2RXH2 3/20 0.42
GAA P10253 1/20 0.42
KEAP1 Q14145 1/20 0.41
TSHR P16473 4/20 0.40
CYP3A4 P08684 3/20 0.40
ATM Q13315 2/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
CDC25B P30305 1/20 0.40
CYP2A6 P11509 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87812 0.84 KDM4E (0.52) HSD17B10ALDH1A1HPGDCYP1A2KDM4E
SCHEMBL14842334 0.84 ALDH1A1 (0.39) HSD17B10ALDH1A1HPGDCYP1A2THRB
SCHEMBL2390408 0.81 HPRT1 (0.52) HSD17B10ALDH1A1HPGDCYP1A2THRB
SCHEMBL4077152 0.80 ALDH1A1 (0.47) HSD17B10ALDH1A1HPGDCYP1A2THRB
SCHEMBL28134582 0.78 KDM4E (0.42) HSD17B10ALDH1A1HPGDCYP1A2KDM4E
SCHEMBL4071126 0.76 ALDH1A1 (0.54) HSD17B10ALDH1A1HPGDCYP1A2THRB
SCHEMBL29458868 0.75 HSD17B10 (0.59) HSD17B10ALDH1A1HPGDCYP1A2THRB
SCHEMBL16194590 0.75 HSD17B10 (0.48) HSD17B10ALDH1A1HPGDCYP1A2THRB
SCHEMBL11463688 0.72 L3MBTL1 (0.37) HSD17B10ALDH1A1HPGDKDM4EGAA
SCHEMBL780090 0.72 ALDH1A1 (0.50) HSD17B10ALDH1A1HPGDCYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-12-23 US disclosed
EP-3858909-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-08-04 EP disclosed
CN-112839988-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2021-05-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF NOC2L, RIF1, NAP1L1 HSD17B10 3823/4885ALDH1A1 2699/4885HPGD 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.